| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
La Jolla Institute for Experimental Medicine, La Jolla, California 92037 [P. B., P. S.], and Genentech, Inc., South San Francisco, California 94080 [K. J. H., N. F.]
In the present study, we evaluated the effects of a neutralizing antivascular endothelial growth factor (anti-VEGF) antibody on angiogenesis and growth of tumor spheroids using an intravital microscopic technique permitting noninvasive, in vivo and in situ study of tumor angiogenesis and tumor growth in conscious mice. Tumor spheroids of the human rhabdomyosarcoma cell line A673, with a diameter between 600 and 1000 µm, were implanted in dorsal skinfold chambers inserted on Beige nude/xid mice. Tumor cells were prelabeled with a fluorescent vital dye [(5-(and-6)-((4-chloromethyl)benzoyl)amino)tetramethylrhodamine], which allowed estimation of the growth of the implanted tumor spheroids. Treatment (i.p.) with the monoclonal antibody A4.6.1, specific for VEGF, completely inhibited neovascularization of the microtumors and suppressed their growth to the extent that tumors implanted in treated animals leveled off at a volume less than 1 mm3, i.e., the anti-VEGF antibody dramatically changed the growth characteristics of the tumor line from being a rapidly growing malignancy to a dormant microcolony.
1 To whom requests for reprints should be addressed, at La Jolla Institute for Experimental Medicine, 11077 North Torrey Pines Road, La Jolla, CA 92037. Phone: (619) 587-8788; Fax: (619) 458-9072.
Received 4/12/96. Accepted 7/ 2/96.
This article has been cited by other articles:
|
|
 |
|
  S. Akhtar, S. M. Meeran, N. Katiyar, and S. K. Katiyar Grape Seed Proanthocyanidins Inhibit the Growth of Human Non-Small Cell Lung Cancer Xenografts by Targeting Insulin-Like Growth Factor Binding Protein-3, Tumor Cell Proliferation, and Angiogenic Factors Clin. Cancer Res., February 1, 2009; 15(3): 821 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Schilder, M. W. Sill, R. B. Lee, T. J. Shaw, M. K. Senterman, A. J. Klein-Szanto, Z. Miner, and B. C. Vanderhyden Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., July 10, 2008; 26(20): 3418 - 3425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Duncan, A. Al-Attar, P. Rolland, I. V. Scott, S. Deen, D. T.Y. Liu, I. Spendlove, and L. G. Durrant Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies? Clin. Cancer Res., May 15, 2008; 14(10): 3030 - 3035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hos, F. Bock, T. Dietrich, J. Onderka, F. E. Kruse, K.-H. Thierauch, and C. Cursiefen Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 1836 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Singh, M. Gu, and R. Agarwal Silibinin Inhibits Colorectal Cancer Growth by Inhibiting Tumor Cell Proliferation and Angiogenesis Cancer Res., March 15, 2008; 68(6): 2043 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Fuster, L. Wang, J. Castagnola, L. Sikora, K. Reddi, P. H.A. Lee, K. A. Radek, M. Schuksz, J. R. Bishop, R. L. Gallo, et al. Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis J. Cell Biol., May 7, 2007; 177(3): 539 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Hefler, A. Mustea, D. Konsgen, N. Concin, B. Tanner, R. Strick, G. Heinze, C. Grimm, E. Schuster, C. Tempfer, et al. Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer Clin. Cancer Res., February 1, 2007; 13(3): 898 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dalal, A. M. Berry, C. J. Cullinane, D. C. Mangham, R. Grimer, I. J. Lewis, C. Johnston, V. Laurence, and S. A. Burchill Vascular Endothelial Growth Factor: A Therapeutic Target for Tumors of the Ewing's Sarcoma Family Clin. Cancer Res., March 15, 2005; 11(6): 2364 - 2378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fang, C. Xia, Z. Cao, J. Z. Zheng, E. Reed, and B.-H. Jiang Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways FASEB J, March 1, 2005; 19(3): 342 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-P. Gerber and N. Ferrara Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies Cancer Res., February 1, 2005; 65(3): 671 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Heymach, J. Desai, J. Manola, D. W. Davis, D. J. McConkey, D. Harmon, D. P. Ryan, G. Goss, T. Quigley, A. D. Van den Abbeele, et al. Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas Clin. Cancer Res., September 1, 2004; 10(17): 5732 - 5740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ferrara Vascular Endothelial Growth Factor: Basic Science and Clinical Progress Endocr. Rev., August 1, 2004; 25(4): 581 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sako, J. Kitayama, H. Koyama, H. Ueno, H. Uchida, H. Hamada, and H. Nagawa Transduction of Soluble Flt-1 Gene to Peritoneal Mesothelial Cells Can Effectively Suppress Peritoneal Metastasis of Gastric Cancer Cancer Res., May 15, 2004; 64(10): 3624 - 3628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Levin, L. Sikora, L. Ding, S. P. Rao, and P. Sriramarao Suppression of Tumor Growth and Angiogenesis in Vivo by a Truncated Form of 24-kd Fibroblast Growth Factor (FGF)-2 Am. J. Pathol., April 1, 2004; 164(4): 1183 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-H. Tseng, S.-M. Lin, J.-C. Chen, Y.-H. Su, H.-Y. Huang, C.-K. Chen, P.-Y. Lin, and Y. Chen Resveratrol Suppresses the Angiogenesis and Tumor Growth of Gliomas in Rats Clin. Cancer Res., March 15, 2004; 10(6): 2190 - 2202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cuadros, A. L. Dominguez, G. I. Frost, P. Borgstrom, and J. Lustgarten Cooperative Effect between Immunotherapy and Antiangiogenic Therapy Leads to Effective Tumor Rejection in Tolerant Her-2/neu Mice Cancer Res., September 15, 2003; 63(18): 5895 - 5901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Braga-Basaria and M. D. Ringel Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1947 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Tosato Interferon-{alpha} Is Implicated in the Transcriptional Regulation of Vascular Endothelial Growth Factor J Natl Cancer Inst, March 19, 2003; 95(6): 420 - 421. [Full Text] [PDF]
|
|
|
|
|
|
E. Barbera-Guillem, J. K. Nyhus, C. C. Wolford, C. R. Friece, and J. W. Sampsel Vascular Endothelial Growth Factor Secretion by Tumor-infiltrating Macrophages Essentially Supports Tumor Angiogenesis, and IgG Immune Complexes Potentiate the Process Cancer Res., December 1, 2002; 62(23): 7042 - 7049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Gao, B.-H. Jiang, S. S. Leonard, L. Corum, Z. Zhang, J. R. Roberts, J. Antonini, J. Z. Zheng, D. C. Flynn, V. Castranova, et al. p38 Signaling-mediated Hypoxia-inducible Factor 1alpha and Vascular Endothelial Growth Factor Induction by Cr(VI) in DU145 Human Prostate Carcinoma Cells J. Biol. Chem., November 15, 2002; 277(47): 45041 - 45048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Gao, M. Ding, J. Z. Zheng, Z. Zhang, S. S. Leonard, K. J. Liu, X. Shi, and B.-H. Jiang Vanadate-induced Expression of Hypoxia-inducible Factor 1alpha and Vascular Endothelial Growth Factor through Phosphatidylinositol 3-Kinase/Akt Pathway and Reactive Oxygen Species J. Biol. Chem., August 23, 2002; 277(35): 31963 - 31971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Restucci, S. Papparella, P. Maiolino, and G. De Vico Expression of Vascular Endothelial Growth Factor in Canine Mammary Tumors Vet. Pathol., July 1, 2002; 39(4): 488 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Lee, D. C. Kim, M. S. Gee, H. M. Saunders, C. M. Sehgal, M. D. Feldman, S. R. Ross, and W. M. F. Lee Interleukin-12 Inhibits Angiogenesis and Growth of Transplanted but not in Situ Mouse Mammary Tumor Virus-induced Mammary Carcinomas Cancer Res., February 1, 2002; 62(3): 747 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Yao, S. E. Pike, and G. Tosato Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function J. Leukoc. Biol., January 1, 2002; 71(1): 47 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Mahasreshti, J. G. Navarro, M. Kataram, M. H. Wang, D. Carey, G. P. Siegal, M. N. Barnes, D. M. Nettelbeck, R. D. Alvarez, A. Hemminki, et al. Adenovirus-mediated Soluble FLT-1 Gene Therapy for Ovarian Carcinoma Clin. Cancer Res., July 1, 2001; 7(7): 2057 - 2066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Hernandez, O. V. Volpert, M. A. Iniguez, E. Lorenzo, S. Martinez-Martinez, R. Grau, M. Fresno, and J. M. Redondo Selective Inhibition of Vascular Endothelial Growth Factor-Mediated Angiogenesis by Cyclosporin a: Roles of the Nuclear Factor of Activated T Cells and Cyclooxygenase 2 J. Exp. Med., March 5, 2001; 193(5): 607 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Giavazzi, R. Giuliani, D. Coltrini, M. R. Bani, C. Ferri, B. Sennino, M. P. M. Tosatti, A. Stoppacciaro, and M. Presta Modulation of Tumor Angiogenesis by Conditional Expression of Fibroblast Growth Factor-2 Affects Early but not Established Tumors Cancer Res., January 1, 2001; 61(1): 309 - 317. [Abstract] [Full Text]
|
|
|
|
|
|
R. A. Brekken, J. P. Overholser, V. A. Stastny, J. Waltenberger, J. D. Minna, and P. E. Thorpe Selective Inhibition of Vascular Endothelial Growth Factor (VEGF) Receptor 2 (KDR/Flk-1) Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth in Mice Cancer Res., September 1, 2000; 60(18): 5117 - 5124. [Abstract] [Full Text]
|
|
|
|
|
|
S. Shiose, T. Sakamoto, H. Yoshikawa, Y. Hata, Y. Kawano, T. Ishibashi, H. Inomata, K. Takayama, and H. Ueno Gene Transfer of a Soluble Receptor of VEGF Inhibits the Growth of Experimental Eyelid Malignant Melanoma Invest. Ophthalmol. Vis. Sci., August 1, 2000; 41(9): 2395 - 2403. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Kubo, T. Fujiwara, L. Jussila, H. Hashi, M. Ogawa, K. Shimizu, M. Awane, Y. Sakai, A. Takabayashi, K. Alitalo, et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis Blood, July 15, 2000; 96(2): 546 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Ke, Y.-X. Shi, S.-A. Im, X. Chen, and W. K. A. Yung The Relevance of Cell Proliferation, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor Production to Angiogenesis and Tumorigenicity in Human Glioma Cell Lines Clin. Cancer Res., June 1, 2000; 6(6): 2562 - 2572. [Abstract] [Full Text]
|
|
|
|
|
|
K. Takayama, H. Ueno, Y. Nakanishi, T. Sakamoto, K. Inoue, K. Shimizu, H. Oohashi, and N. Hara Suppression of Tumor Angiogenesis and Growth by Gene Transfer of a Soluble Form of Vascular Endothelial Growth Factor Receptor into a Remote Organ Cancer Res., April 1, 2000; 60(8): 2169 - 2177. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Wood, G. Bold, E. Buchdunger, R. Cozens, S. Ferrari, J. Frei, F. Hofmann, J. Mestan, H. Mett, T. O’Reilly, et al. PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration Cancer Res., April 1, 2000; 60(8): 2178 - 2189. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. McMahon VEGF Receptor Signaling in Tumor Angiogenesis Oncologist, April 1, 2000; 5(90001): 3 - 10. [Abstract] [Full Text]
|
|
|
|
|
|
G. Gasparini Prognostic Value of Vascular Endothelial Growth Factor in Breast Cancer Oncologist, April 1, 2000; 5(90001): 37 - 44. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. S. Kerbel Tumor angiogenesis: past, present and the near future Carcinogenesis, March 1, 2000; 21(3): 505 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Wedge, D. J. Ogilvie, M. Dukes, J. Kendrew, J. O. Curwen, L. F. Hennequin, A. P. Thomas, E. S. E. Stokes, B. Curry, G. H. P. Richmond, et al. ZD4190: An Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-Spectrum Antitumor Efficacy Cancer Res., February 1, 2000; 60(4): 970 - 975. [Abstract] [Full Text]
|
|
|
|
|
|
G. J. Brewer, R. D. Dick, D. K. Grover, V. LeClaire, M. Tseng, M. Wicha, K. Pienta, B. G. Redman, T. Jahan, V. K. Sondak, et al. Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anticopper, Antiangiogenic Agent: Phase I Study Clin. Cancer Res., January 1, 2000; 6(1): 1 - 10. [Abstract] [Full Text]
|
|
|
|
|
|
R. Abramovitch, H. Dafni, E. Smouha, L. E. Benjamin, and M. Neeman In Vivo Prediction of Vascular Susceptibility to Vascular Endothelial Growth Factor Withdrawal: Magnetic Resonance Imaging of C6 Rat Glioma in Nude Mice Cancer Res., October 1, 1999; 59(19): 5012 - 5016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Gabrilovich, T. Ishida, S. Nadaf, J. E. Ohm, and D. P. Carbone Antibodies to Vascular Endothelial Growth Factor Enhance the Efficacy of Cancer Immunotherapy by Improving Endogenous Dendritic Cell Function Clin. Cancer Res., October 1, 1999; 5(10): 2963 - 2970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. E. Tsopanoglou and M. E. Maragoudakis On the Mechanism of Thrombin-induced Angiogenesis. POTENTIATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY ON ENDOTHELIAL CELLS BY UP-REGULATION OF ITS RECEPTORS J. Biol. Chem., August 20, 1999; 274(34): 23969 - 23976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Weltermann, M. Wolzt, K. Petersmann, C. Czerni, U. Graselli, K. Lechner, and P. A. Kyrle Large Amounts of Vascular Endothelial Growth Factor at the Site of Hemostatic Plug Formation In Vivo Arterioscler Thromb Vasc Biol, July 1, 1999; 19(7): 1757 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Gorski, M. A. Beckett, N. T. Jaskowiak, D. P. Calvin, H. J. Mauceri, R. M. Salloum, S. Seetharam, A. Koons, D. M. Hari, D. W. Kufe, et al. Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation Cancer Res., July 1, 1999; 59(14): 3374 - 3378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Grunstein, W. G. Roberts, O. Mathieu-Costello, D. Hanahan, and R. S. Johnson Tumor-derived Expression of Vascular Endothelial Growth Factor Is a Critical Factor in Tumor Expansion and Vascular Function Cancer Res., April 1, 1999; 59(7): 1592 - 1598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hazelton, R. F. Nicosia, and S. V. Nicosia Vascular Endothelial Growth Factor Levels in Ovarian Cyst Fluid Correlate with Malignancy Clin. Cancer Res., April 1, 1999; 5(4): 823 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lozonschi, M. Sunamura, M. Kobari, S. Egawa, L. Ding, and S. Matsuno Controlling Tumor Angiogenesis and Metastasis of C26 Murine Colon Adenocarcinoma by a New Matrix Metalloproteinase Inhibitor, KB-R7785, in Two Tumor Models Cancer Res., March 1, 1999; 59(6): 1252 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yao, C. Sgadari, K. Furuke, E. T. Bloom, J. Teruya-Feldstein, and G. Tosato Contribution of Natural Killer Cells to Inhibition of Angiogenesis by Interleukin-12 Blood, March 1, 1999; 93(5): 1612 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dagher and L. Helman Rhabdomyosarcoma: An Overview Oncologist, February 1, 1999; 4(1): 34 - 44. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. M. Ryan, D. B. Eppler, K. E. Hagler, R. H. Bruner, P. J. Thomford, R. L. Hall, G. M. Shopp, and C. A. O'Neill Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal Antibody Toxicol Pathol, January 1, 1999; 27(1): 78 - 86. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Ishida, T. Oyama, D. P. Carbone, and D. I. Gabrilovich Defective Function of Langerhans Cells in Tumor-Bearing Animals Is the Result of Defective Maturation from Hemopoietic Progenitors J. Immunol., November 1, 1998; 161(9): 4842 - 4851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Stratmann, W. Risau, and K. H. Plate Cell Type-Specific Expression of Angiopoietin-1 and Angiopoietin-2 Suggests a Role in Glioblastoma Angiogenesis Am. J. Pathol., November 1, 1998; 153(5): 1459 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Roca, T. P. Gavin, M. Jordan, N. Siafakas, H. Wagner, H. Benoit, E. Breen, and P. D. Wagner Angiogenic growth factor mRNA responses to passive and contraction-induced hyperperfusion in skeletal muscle J Appl Physiol, September 1, 1998; 85(3): 1142 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Seghezzi, S. Patel, C. J. Ren, A. Gualandris, G. Pintucci, E. S. Robbins, R. L. Shapiro, A. C. Galloway, D. B. Rifkin, and P. Mignatti Fibroblast Growth Factor-2 (FGF-2) Induces Vascular Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of Forming Capillaries: An Autocrine Mechanism Contributing to Angiogenesis J. Cell Biol., June 29, 1998; 141(7): 1659 - 1673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Benjamin and E. Keshet Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal PNAS, August 5, 1997; 94(16): 8761 - 8766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Maxwell, G. U. Dachs, J. M. Gleadle, L. G. Nicholls, A. L. Harris, I. J. Stratford, O. Hankinson, C. W. Pugh, and P. J. Ratcliffe Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth PNAS, July 22, 1997; 94(15): 8104 - 8109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ferrara and T. Davis-Smyth The Biology of Vascular Endothelial Growth Factor Endocr. Rev., February 1, 1997; 18(1): 4 - 25. [Abstract] [Full Text]
|
|
|
|
|
|
H. Gille, J. Kowalski, B. Li, J. LeCouter, B. Moffat, T. F. Zioncheck, N. Pelletier, and N. Ferrara Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A REASSESSMENT USING NOVEL RECEPTOR-SPECIFIC VASCULAR ENDOTHELIAL GROWTH FACTOR MUTANTS J. Biol. Chem., January 26, 2001; 276(5): 3222 - 3230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Papetti and I. M. Herman Mechanisms of normal and tumor-derived angiogenesis Am J Physiol Cell Physiol, May 1, 2002; 282(5): C947 - C970. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
